Afatinib API CAS 439081-18-2

 

1. Afatinib powder is an irreversible drug for NSCLCm+ patients with advanced EGFR mutation. The analysis of biomarkers shows that CISH may be a promising marker of the reaction of afatinib, and the neoadjuvant treatment of afatinib will also cause the dynamic changes of tumor microenvironment.
2. Non-small cell lung cancer is one of the most common types of lung cancer cases, and many patients have EGFR mutations. At this time, EGFR-TKI is recommended as the first choice for treatment.
3. Targeted therapy is an important method for patients with metastatic lung adenocarcinoma. As the second generation EGFR-TKI, alfatinib shows better effect, especially for patients with alveolar cell carcinoma. Targeted therapy is of great significance in the treatment of lung cancer, and the effect is remarkable for some sensitive people.

 

Afatinib powder is an irreversible ErbB family blocker, which can suppress information transmission and block the main channels related to the growth and division of cancer cells. Because it can be triggered by multiple homodimers and heterodimers through the ErbB family information transmission mechanism, simultaneously inhibiting multiple ErbB family members (such as EGFR, HER2, ErbB3 and ErbB4) can effectively interrupt the downstream information transmission.

In cancer cells, the function of ErbB family is often out of balance. When the factors controlling the cell growth mechanism are over-expressed or abnormal, it is possible to cause various solid tumors. Overexpression of receptors will stimulate the intracellular information transmission beyond the normal level, lead to uncontrolled growth, migration and metastasis of tumor cells and inhibit their apoptosis.

 

1. Prolonged progression-free survival (PFS): In many clinical trials, afatinib showed a longer progression-free survival compared with traditional ALK inhibitors such as Crizotinib. This means that the tumor progresses for a longer period of time after the patient is treated with afatinib.

2. Improve overall survival (OS): Patients treated with afatinib usually show a longer overall survival, especially those who switch to afatinib after the disease progresses.

3. Good tolerance: Compared with other ALK inhibitors, afatinib usually has better tolerance and reduces some common adverse reactions, such as gastrointestinal discomfort and visual impairment.

4. Central nervous system control: Afatinib can penetrate the blood-brain barrier, so it may also have a good control effect on patients with central nervous system metastasis.

5. Suitable for patients at different stages: Afatinib has been proved to be effective for untreated ALK-positive NSCLC patients and those who have received other treatments but have relapsed or metastasized.

Generally speaking, afatinib is an effective treatment option, which can improve the survival and quality of life of patients with ALK positive non-small cell lung cancer.